[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"type-2-diabetes-with-chronic-kidney-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:type-2-diabetes-with-chronic-kidney-disease":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100644444","phase-3-a-phase-iii-study-to-investigate-the-efficacy-and-safety-of-elecoglipron-compared-with-placebo-in-adults-with-type-2-diabetes-mellitus-and-impaired-renal-function-on-background-dapagliflozin-100644444",false,"NCT07662135","A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin","A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin (Eluminate-4)","Eluminate-4","Inclusion Criteria:\n\n* Diagnosed with Type 2 Diabetes Mellitus for at least 90 days prior to screening\n* On SGTL2i or SGLT2i-naïve and other glucose lowering medication(s)\n* HbA1c value:\n\n  1. On stable dose of SGLT2i ≥ 7.0 % to ≤ 10.5% (53 to 91.3 mmol\u002Fmol)\n  2. SGLT2i-naive ≥ 7.5% to ≤ 10.5% (58 to 91.3 mmol\u002Fmol)\n* Impaired renal function\n* Body mass index (BMI) of ≥ 23 kg\u002Fm2 at screening\n* Stable body weight (self-reported or documented) for 90 days prior to screening\n\nExclusion Criteria:\n\n* Type 1 Diabetes, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma\n* Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and\u002For macular edema\n* Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms\n* Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying\n* History of acute or chronic pancreatitis\n* Severe congestive heart failure (New York Heart Association IV)\n* History\u002Ffamily history of medullary thyroid cancer or multiple endocrine neoplasia type 2","ALL","18 Years",{"count":20,"type":21},900,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron, compared with placebo in adults with type 2 diabetes mellitus (T2DM) and impaired renal function, who are or will be on a background of sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin 10 mg as per guideline directed medical therapy (GDMT) for chronic kidney disease (CKD). Additionally, participants are on other glucose-lowering medication(s).",[27,28],"Type 2 Diabetes Mellitus","Type 2 Diabetes With Chronic Kidney Disease","NOT_YET_RECRUITING","2026-06-18",{"date":32,"type":33},"2026-06-23","ACTUAL",{"date":35,"type":21},"2026-07-06",{"date":37,"type":21},"2028-07-13",{"name":39,"class":40},"AstraZeneca","INDUSTRY",162]